Eluvia Drug-Eluting Stent Gains Reimbursement in Belgium

 

February 11, 2019—Boston Scientific Corporation announced that it has received reimbursement approval in Belgium for its Eluvia drug-eluting vascular stent system for treating superficial femoral artery and/or proximal popliteal artery lesions. The reimbursement is effective from January 1, 2019, and was obtained based on the favorable results demonstrated by Eluvia in the IMPERIAL trial, the company noted. The IMPERIAL trial compared two paclitaxel-eluting peripheral stent systems—Eluvia and Zilver PTX (Cook Medical)—and showed improved primary patency and freedom from target lesion revascularization for Eluvia at 1 year.

These data were presented at CIRSE 2019 and TCT 2019, as well as published in The Lancet.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.